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Heart failure represents a significant medi-
cal and economic burden and is also an 
important cause of mortality and morbid-
ity. The advances in treating coronary ar-
tery disease mainly pertaining to modern 
invasive cardiology significantly reduced 
the mortality from coronary atherosclero-
sis, but on the other side caused an increase 
in incidence and prevalence of congestive 
heart failure. Heart failure is a disease of 
the elderly. In that population the inci-
dence is 10 in 1000 patients older than 65 
years and has a high five-year mortality de-
spite all modern treatment modalities. (1)
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INTRODUCTION
Heart failure is a clinical syndrome in 
which a clinical evaluation of signs and 
symptoms represents a cornerstone in 
making the diagnosis, guiding of treat-
ment and estimating a patient’s prognosis. 
Determining left ventricular filling pres-
sures by using non-invasive or invasive 
techniques is the most important element 
in choosing the best treatment option. In 
that aspect, the degree of congestion be-
comes the key element in the overall clini-
cal picture that decides on the need for 
hospitalization.
DISCUSSION
Congestive heart failure is in essence a 
problem of congestion and volume over-
load. The large number of patients suffer-
ing from this syndrome dictates the need 
for effective methods of detecting and 
treating congestion to be found. Heart 
failure patients are often rehospitalized, 
mirroring the still insufficient tools for 
volume status assessment in that specific 
population. Evaluation of congestion re-
mains a challenge. Every patient is unique 
in his or her body habitus and comorbidi-
ties, which makes the clinical evaluation of 
congestion difficult and expresses the need 
for using various methods. (2) The lack of 
a singular clinical tool should stimulate 
the emergence of novel methods pertain-
ing to implantable devices which can give 
an accurate measurement of volume load 
over time. Today certain types of resyn-
chronization pacemakers can give precise 
measurement of volume status using tran-
sthoracic impedance. It is reasonable to 
expect that these devices will become the 
cornerstone of treatment decision making 
in the future.
Heart failure is mainly a clinical diagnosis 
and no single diagnostic test can confirm 
its presence or absence. The most frequent 
clinical findings are related to decreased 
exercise tolerance or fluid retention. In 
that respect the New York Heart Associa-
tion (NYHA) classification of heart failure 
is widely used in clinical practice and in 
clinical studies to quantify the degree of 
dyspnoea and of heart failure. Dyspnoea, 
the main symptom of left ventricular fail-
ure, may manifest with progressively in-
creasing severity as exertional dyspnoea, 
orthopnoea, paroxysmal nocturnal dysp-
noea, dyspnoea at rest or acute pulmonary 
oedema. Common extracardiac signs and 
symptoms of heart failure include anorex-
ia, nausea, weight loss, abdominal disten-
sion, fatigue, weakness, oliguria, nocturia, 
and cerebral symptoms ranging from anxi-
ety to memory impairment and confusion. 
Orthopnea is an early symptom of heart 
failure and may be defined as dyspnea 
that develops in the supine position and 
is relieved with elevation of upper body. 
Blood is displaced from the extrathoracic 
compartment to the thoracic vasculature, 
and the failing left ventricle, operating 
on the flat portion of the Frank-Starling 
curve, cannot accept and pump out the 
extra volume of blood delivered to it. As a 
result, pulmonary capillary pressure rises, 
causing interstitial pulmonary oedema, 
reduced pulmonary compliance, increased 
airway resistance, and dyspnoea. In ad-
vanced LV failure, orthopnoea may be so 
severe that the patient cannot lie down 
and must sleep sitting up. Cough, particu-
larly during supine position, may be an 
orthopnoea variant. It can be caused by 
pulmonary congestion and is relieved by 
the treatment of heart failure. Paroxysmal 
nocturnal dyspnoea occurs at night and 
is defined as the sudden awakening with 
a feeling of severe anxiety and air short-
age. The patient must sit up in bed to catch 
some air. Bronchospasm is often present 
increasing respiratory work. On lung aus-
cultation, the bronchospasm of heart fail-
ure can be difficult to distinguish from an 
acute asthma exacerbation, although both 
types of bronchospasm can be present in a 
single patient. In contrast to orthopnoea, 
which may be relieved by immediately 
sitting up in bed, paroxysmal noctur-
nal dyspnoea may require 30 minutes or 
longer in this position for relief. Dyspnoea 
at rest in heart failure is the result of de-
creased pulmonary function secondary to 
increased airway resistance, increased pul-
monary capillary wedge pressure (PCWP) 
and respiratory muscle strength decrease. 
Acute pulmonary oedema is defined as the 
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sudden increase in PCWP (usually more 
than 25 mm Hg) as a result of acute and 
fulminant left ventricular failure. It is a 
medical emergency with a dramatic clini-
cal presentation. The patient is tachyp-
noeic, tachycardic, hypoxic, and coughing, 
with an increased work of breathing and 
with using accessory muscles for breathing 
while expectorating foamy, blood tinged 
sputum.
In addition to previously mentioned symp-
toms and their correlation to heart failure, 
the physical examination and evaluation of 
signs of the disease are a crucial element 
of assessing the presence and the degree of 
congestion. Unfortunately it has significant 
limitations. The assessment of fluid load by 
physical examination consists of several 
components: distention of jugular veins, 
hepatojugular reflux, auscultation of lung 
fields and peripheral oedema. Jugular ve-
nous pressure is estimated from the angle 
of the sternum to the top of the column of 
visible distension, with elevations >2 to 3 
cm being abnormal. Hepatojugular reflux 
is appreciated with palpation of the liver 
and adds to the sensitivity of examination 
of the jugular veins. When clinically noted, 
the presence of jugular venous distention 
is highly sensitive for elevated pulmonary 
capillary wedge pressure (PCWP). (3) 
Oedema is an important finding, usually 
symmetric, beginning with the feet and 
ascending to the abdomen. Unfortunately 
it is not specific and depends on grav-
ity, therefore on the position of the body. 
Many extracardiac diseases like liver, kid-
neys, or vascular system and obesity may 
cause the oedema as well. In such cases, 
using the presence of oedema alone with-
out other signs of volume excess can lead 
to inaccuracies in patient assessment. 
Rales upon lung auscultation, when pre-
sent, are an obvious indicator of hyperv-
olemia. However, they may be absent even 
in the case of obvious worsening of heart 
failure. Rales can be absent in the major-
ity of patients with systolic HF because of 
increased lymphatic drainage and chronic 
perivascular compensation. In conclu-
sion, symptoms and signs do not answer 
the question completely and accurately. 
Large studies dealing with heart failure 
found that dyspnoea as a symptom was 
present in approximately 90% of patients, 
and peripheral oedema in only 2/3 of pa-
tients roughly. Some observational stud-
ies demonstrated however, that half of the 
patients were actually asymptomatic. Con-
sequently, the biggest problem was resid-
ual congestion at discharge as outlined in 
EURObservational Research Programme 
Heart Failure PILOT. Almost one quarter 
of patients had peripheral and pulmonary 
congestion at discharge and these patients 
do die more often according to ACUTE 
HF trial. Can we do better in assessing and 
treating congestion?
The simplest way for evaluating fluid sta-
tus is to monitor weight changes. This can 
be done in and out of hospital, at home by 
the patient or by health care professionals. 
There are also methods of weight moni-
toring that utilize the remote monitoring 
system either with implantable or non-im-
plantable monitoring devices. There is sub-
stantial evidence to support this method, 
showing improvements in mortality rates. 
The European trial (The Trans-European 
Network Homecare Monitoring Study) 
demonstrated that patients randomized 
to home telemonitoring of weight, blood 
pressure, heart rate and rhythm had lower 
mortality rates than usual care patients. In 
contrast, weight measurements can lead to 
inaccurate fluid assessment due to varia-
tions of percentage of body fat. In termi-
nal heart failure patients, cardiac cachexia 
and oedema impede the evaluation of fluid 
status because there may be stable weight 
with worsening symptoms and fluid over-
load.
Apart from clinical examination, there are 
other non-invasive and invasive techniques 
at our disposal. Firstly, there are biomark-
ers. The laboratory measurement of brain 
natriuretic peptide (BNP) was found to 
correlate with the severity of heart failure 
and there were grand expectations in us-
ing BNP to monitor fluid status. In reality, 
BNP values have been shown to decrease 
with the use of beta-blockers and no study 
has shown consistent and statistically sig-
nificant decreases in wedge pressure with 
decreased BNP levels. Improved BNP does 
however correlate with improved NYHA 
functional status and serial measurements 
do have a role in chronic heart failure man-
agement but, as with other physical exami-
nations and symptoms, it is not a sufficient 
and stand-alone parameter. Therefore, 
biomarkers are an adjunct in making the 
diagnosis, specifically when evaluating 
dyspnoea and ruling out other differen-
tial causes apart from heart failure. Still, 
caution is advised. There is a grey zone of 
prognostic uncertainty in the spectrum of 
laboratory values of BNP between 100 and 
400pg/nml. Substantiating that there is the 
REDHOT study in which physicians who 
had to assess the degree of heart failure 
were blinded to the BNP levels. Based sole-
ly on clinical assessment, the group of pa-
tients who were discharged as having only 
mild heart failure had in fact 22% higher 
BNP levels than the group declared more 
significantly decompensated. One must 
also bear in mind that BNP levels are pro-
portional to body mass index (BMI), so in 
patients above 35 BMI, the cut off value of 
BNP should be doubled. BNP levels on the 
other hand, correlate with invasively ac-
quired PCWP. Therefore, serial measure-
ments of BNP during hospitalization have 
a role of assessing the patient’s readiness to 
be discharged. In that spectrum, the pre-
discharge value may be the most important 
as the majority of heart failure patients will 
eventually be readmitted, and it was found 
that an elevated pre-discharge BNP value 
has an increased likelihood of rehospitali-
zation and/or death. (4)
Echocardiography, as a ubiquitous method 
in cardiology, can provide important infor-
mation on the fluid status in heart failure. 
Estimated right ventricular or pulmonary 
artery pressures may be used to estimate 
filling pressures and mitral inflow Dop-
pler imaging provides information about 
diastolic function. The most often used 
echocardiographic measurements relate 
to parameters regarding the inferior vena 
cava diameter and left ventricle diastolic 
diameter. In that aspect there are static 
measurements (IVC diameter, central ve-
nous pressure and end-diastolic left ventri-
cle diameter) which have no value in heart 
failure patients whatsoever. The mainstay 
of assessment remains with dynamic pa-
rameters: IVC distensibility index, delta 
VTI or Vmax in left ventricular outflow 
tract following passive leg raise maneuver. 
These parameters may be used to help an-
swer the question of fluid responsiveness 
or fluid overload, but also have significant 
limitations regarding spontaneous breath-
ing or mechanical ventilation and the ex-
istence of pre-existent cardiac disease. In 
these circumstances the echo-values ac-
quired will be inaccurate, so the clinician 
should be aware of those limitations.
Radiographic findings of CHF may be 
present during worsening episodes. The 
typical findings of perivascular congestion, 
Kerley B lines, pleural effusions, and ful-
minant oedema are definitive in their di-
agnosis of congestion. Their absence, how-
ever, is not a reliable method for assessing 
volume status. Even in patients with a 
markedly elevated PCWP, radiographic 
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evidence of congestion may be absent in 
almost half of patients.
The pulmonary artery catheter (PAC), in-
troduced in 1970, enabled accurate hemo-
dynamic measurements of the right and left 
heart beat to beat. Despite that, today right 
heart catheterisationhas a questionable 
role in the intensive management of heart 
failure patients. A metaanalysis of multiple 
randomized controlled trials did not dem-
onstrate a superiority of PAC regarding 
mortality. (4) The 2008 European Society 
of Cardiology guidelines for the diagnosis 
and treatment of acute and chronic heart 
failure recommended PAC with a class IIa 
recommendation (level of evidence C) in 
haemodynamically unstable patients who 
are not responding as expected to conven-
tional treatment. PAC placement should be 
considered in distinguishing cardiogenic 
from non-cardiogenic pulmonary oedema 
in complex patients with concurrent cardi-
ac and pulmonary disease, especially when 
echo-measurements are difficult to obtain 
or when levels of BNP are inconclusive. 
(6) The PAC remains the principal means 
of assessing pulmonary vascular resist-
ance and reactivity in patients undergoing 
evaluation for cardiac transplantation and 
occasionally for placement of a left ventric-
ular assist device. In patients with suspect-
ed pulmonary hypertension, right-heart 
catheterisation is required to confirm the 
presence of PH, establish the specific di-
agnosis, and determine the severity of PH. 
In addition, in patients with suspected PH 
right-heart catheterisation is required to 
guide the therapy. The insertion of a PAC 
for the diagnosis of acute heart failure is 
usually unnecessary. In myocardial infarc-
tion complicated by cardiogenic shock or 
progressive hypotension, right heart cath-
eterisation was considered as a class I in-
dication in previous guidelines. However, 
in view of the recent data concerning PAC 
use, such a recommendation is no longer 
included in the recently published guide-
lines on myocardial infarction. (7)
CONCLUSION
HF patients are complex to treat, and a 
proper assessment of fluid status by physi-
cal examination alone can be difficult and 
misleading, especially in the population of 
obese patients and patients with chronic 
lung disease. Physical examination re-
mains the primary tool of assessment in 
heart failure. Daily weight measurements 
serve as a useful outpatient management 
tool. Novel methods for home monitoring 
of volume status emerge to complement 
the physical examination and allow us to 
be aware of the problem before it becomes 
manifest and therefore prevent hospitaliza-
tion. The management of volume status in 
heart failure patients is crucial. Significant 
congestion at discharge is something we 
must try to reduce as it represents a poor 
prognostic factor. The goal in the future 
lies in embracing novel technologies in or-
der to treat patients in a way that protects 
the quality of life and extends it in an op-
timal way.
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